How many proton beam therapy centers are enough? The United States now has 5 in operation with at least 10 more on the horizon (see Table 1). The price tag is mind-boggling, upward of $200 million for a single PBT facility. To justify this huge capital investment, a proton center needs a strategic model, in other words, a high-volume disease, such as prostate cancer.
Promoted as reducing the risk of the side effects men fear most-such as impotence-more and more prostate cancer patients are choosing proton therapy, raising concern that proton centers are being built using prostate cancer as a de facto business model.
“Proton therapy has theoretical advantages in prostate cancer, but it should be thoroughly investigated by those with no commercial bias,” Anthony Zietman, MD, Department of Radiation Oncology, Massachusetts General Hospital, told Oncology News International in an interview. The Francis H. Burr Proton Therapy Center is located at Mass General.
Table 1. Proton facilities operating in the US
- The James M. Slater, MD, Proton Treatment and Research Center - Loma Linda, California
- Midwest Proton Radiotherapy Institute at Indiana University - Bloomington, Indiana
- Francis H. Burr Proton Therapy Center - Massachusetts General Hospital-Harvard, Boston
- M.D. Anderson Proton Therapy Center - Houston
- University of Florida Proton Therapy Institute - Jacksonville, Florida
Selected proton facilities under development in the US
- The Roberts Proton Therapy Center at University of Pennsylvania Health System, Philadelphia
- Hampton University, Hampton, Virginia
- Seattle Cancer Care Alliance
- The Oklahoma ProCure Treatment Center, Oklahoma City
- Siteman Cancer Center – St. Louis, Missouri.
- The Northern Illinois Proton Treatment and Research Center -- Chicago
Proponents of PBT contend that its unique dose-distribution makes it the best option in several anatomically difficult cancers, such as skull-based tumors, ocular tumors, and pediatric malignancies. For example, researchers at Harvard reported excellent long-term results with minimal side effects in treating skull-based tumors with proton therapy (Hoch et al: Am J Surg Pathol 30:811-818, 2006). However, the cancers in which proton therapy have proven efficacy over other therapies are relatively rare.
Dr. Zietman stressed that while there is increasing enthusiasm for proton therapy, there have been no randomized trials comparing the efficacy of protons and IMRT in localized prostate cancer.
“PBT has tremendous promise in prostate cancer, but there’s a high price tag, so we need to be certain that it’s better than any alternative treatment,” Dr. Zietman said.
Since 1990, when Loma Linda University Medical Center (LLUMC) opened the world’s first hospital-based proton center, about 8,000 US men with prostate cancer have undergone proton therapy. There are 5 proton centers operating in the United States, 3 under construction, and about 10 in the planning stage (Table 1).
According to Jon Slater, president and CEO of Optivus, the US market is ripe for growth. Optivus is the company that engineered hospital-based proton therapy at Loma Linda. The Loma Linda proton center was recently named for proton therapy pioneer James M. Slater, MD, who is Jon Slater’s father.
“Looking at the history of radiation oncology, in which new modalities offer more precise treatment, I see proton beam therapy as a replacement for x-ray radiation therapy,” Mr. Slater told ONI.
Asked whether the costs of PBT to our healthcare system are justified, Mr. Slater said, “This year, proton therapy will generate about $100 million in clinical revenue out of a system that spends $2 trillion on healthcare. I think if there is interest in cutting costs, one of the last places you should look is proton therapy.”
The allure of PBT
Each year in the United States, more than 180,000 men are diagnosed with prostate cancer, providing a massive potential market for PBT centers. Cancer survivors make powerful arguments for the treatment that saved their lives.
Bob Marckini, a survivor of prostate cancer known as “Proton Bob,” became a dedicated advocate of proton therapy following his treatment at Loma Linda. Seeing his older brother suffer complications of a radical prostatectomy set Mr. Marckini in search of a different clinical path when, shortly after his brother’s ordeal, he also was diagnosed with prostate cancer.
“Seeing my brother after surgery scared me to death. He had lost 6 pints of blood, and he was connected to tubes, drains, and catheters. When I was diagnosed, I immediately began to search for another option,” Mr. Marckini told ONI.
Each doctor consult, however, only added to Mr. Marckini’s confusion. “It seems I was the ideal candidate for surgery, cryotherapy, seeds, and external beam radiation,” he said.
A chemical engineer by profession, Mr. Marckini’s research background helped him wend through a labyrinth of medical opinions. After speaking with dozens of former proton therapy patients, he chose Loma Linda for his treatment, largely based on the belief that PBT offered a better side-effects profile for “the two things men with prostate cancer fear most-impotence and incontinence.”
Mr. Marckini’s positive experience with PBT inspired his 2006 book, You Can Beat Prostate Cancer, and led him to establish a proton therapy advocacy/support group, boasting a worldwide membership of 3,300 men.
Are randomized trials needed?
As use of PBT grows, so does the debate over the need for randomized clinical trials comparing proton therapy with conventional x-ray therapy. Clinicians who oppose randomized trials make the case that scientific knowledge dictates that protons can provide superior therapy, compared with x-rays, in almost all clinical situations.
Loma Linda’s medical director, Jerry Slater, MD (whose brother is Jon Slater), said in an interview that proton beams offer significant advantages in sparing normal tissue. Unlike x-rays, the peak proton dose occurs precisely within the tumor volume.
“It has been shown numerous times that the amount of normal tissue you can miss with proton therapy, compared with other treatments, is a factor of three to four times,” said Dr. Slater, who is also director of clinical affairs for the Department of Radiation Medicine at LLUMC. He believes that a trial looking at equivalent doses of x-rays vs protons would be unethical.
“We didn’t do those trials for IMRT, 3D conformal RT, or cobalt therapy because the end result would be giving patients unnecessary doses of radiation to healthy tissue,” he said.
The University of Florida Proton Therapy Institute, which opened in August 2006, treats an average of 90 patients a day and more than 600 annually. Approximately 70% of patients at the Institute are being treated for prostate cancer, executive director Stuart Klein, MHA, told ONI.
Mr. Klein said that he does not think randomized trials comparing proton therapy with conventional x-ray therapy are needed. “We do, however, support clinical trials in proton therapy for prostate cancer as well as other disease sites,” Mr. Klein said.
In oncology, best practice often trumps economics, and new treatments such as PBT may be introduced into clinical practice without economic analysis. To some clinicians the debate over randomized trials is a smokescreen for the real issue-money.
“To balance out the cost issue between proton therapy and IMRT, you have to separate cost and effectiveness. We do not know the cost of proton therapy because we haven’t yet maximized its effectiveness,” Dr. Jerry Slater said.
To him, the debate over cost is myopic. “What I’m doing today in prostate cancer is not what I’ll be doing 5 or 10 years down the road. I’m looking to reduce the number of treatments per patient. Personally, I think that proton therapy will eventually become our single most cost-effective therapy for prostate cancer,” he said.